Although typical primary isolates of human immunodeficiency virus type 1 (HIV-1) are
relatively neutralization resistant, three human monoclonal antibodies and a small number …

Several reports have described the existence of synergy between neutralizing monoclonal
antibodies (MAbs) against human immunodeficiency virus type 1 (HIV-1). Synergy between …

Attempts to elicit broadly neutralizing antibody responses by human immunodeficiency virus
type 1 (HIV-1) vaccine antigens have been met with limited success. To better understand …

The ability of the broadly neutralizing human immunodeficiency virus type 1 (HIV-1) specific
human monoclonal antibodies (MAbs) b12, 2G12, 2F5, and 4E10 to neutralize recently …

Neutralizing antibody responses to human immunodeficiency virus type 1 (HIV-1) vary
widely and have not been reproducibly associated with prognosis or disease progression …

To examine antibody-mediated neutralization of HIV-1 primary isolates in vitro, we tested
sera and plasma from infected individuals against four clade B primary isolates. These …

Withover A dozen vaccine candidates in clinical trials, including two in phase 2 studies, and
an infrastructure being prepared to accept vaccines for large-scale efficacy trials, the HIV …

HIV-1 is known to show a high degree of genetic diversity, which may have major
implications for disease pathogenesis and prevention. If every divergent isolate represented …

Primary and laboratory-adapted variants of human immunodeficiency virus type 1 (HIV-1)
exhibit a wide range of sensitivities to neutralization by antibodies directed against the viral …

The role of the third variable domain (V3) of gp120 in the neutralization of primary and T-cell
line adapted (TCLA) strains of human immunodeficiency virus type 1 (HIV-1) by serum from …